TNFSF9 and Splenomegaly: Work from the Shirwan lab has elegantly demonstrated the therapeutic ability of a streptavidin-conjugated murine CD137L (SA-mCD137L) complex to induce effective antitumor immune responses.40,41 SA-mCD137L induces less lymphadenopathy and splenomegaly than antibody therapy, suggesting that SA-mCD137L has a higher therapeutic index.